Nippon Shinyaku Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nippon Shinyaku Co., Ltd.
China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Sobi Maintains Grip On RSV Market – For Now
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.
Asarina And Emalex Carry The Torch For Tourette's
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- NS Pharma, Inc.
- Tianjin Nippon Shinyaku Co., Ltd.
- Tianjin NS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.